What is the global market size of Stem Cell Therapy Market?

Stem cell therapy Market size was valued at USD 11 Billion in 2021 and is poised to grow from USD 12.11 Billion in 2022 to USD 26.15 Billion by 2030, at a CAGR of 10.1% during the forecast period (2023-2030).

Who are the key vendors in the Global Stem Cell Therapy Market?

The Global Stem cell therapy Market is highly competitive, with several key players operating in the industry. These companies are actively involved in research and development, strategic collaborations, mergers and acquisitions, and product launches to gain a competitive edge in the market. Here are some prominent players in the stem cell therapy market. The market is dynamic and competitive, with ongoing advancements and new entrants continually shaping the landscape. It is worth noting that the competitive landscape may evolve over time as companies pursue strategic collaborations, expand their product portfolios, and introduce new therapies to address unmet medical needs. 'Novartis AG (Switzerland)', 'Pfizer Inc. (US)', 'Mesoblast Limited (Australia)', 'Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)', 'TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)', 'Gamida Cell Ltd. (Israel)', 'Vericel Corporation (US)', 'Medipost Co., Ltd. (South Korea)', 'Astellas Pharma Inc. (Japan)', 'Osiris Therapeutics, Inc. (US)', 'NuVasive, Inc. (US)', 'Cynata Therapeutics Limited (Australia)', 'Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)', 'Lonza Group Ltd. (Switzerland)', 'Caladrius Biosciences, Inc. (US)', 'Athersys, Inc. (US)', 'Cytori Therapeutics, Inc. (US)', 'Holostem Terapie Avanzate S.r.l. (Italy)', 'Pluristem Therapeutics Inc. (Israel)', 'BioTime, Inc. (US)'.

What is the key driver of Global Stem Cell Therapy Market?

The rising burden of chronic diseases, such as cardiovascular disorders, neurodegenerative conditions, and orthopedic injuries, is a significant driver for the stem cell therapy market. Stem cell therapies offer the potential to regenerate damaged tissues and organs, providing new treatment options for patients with limited or no effective alternatives.

What is the key market trend for Global Stem Cell Therapy Market?

Increased Focus on Allogeneic Therapies: Allogeneic stem cell therapies, which use cells from a donor, have gained traction in the market. This approach offers advantages such as standardized and readily available cell sources, reduced manufacturing costs, and potential off-the-shelf treatments. Many companies are shifting their focus towards developing allogeneic cell therapy products, leading to an expanding pipeline of clinical trials and product development in this area.

Which region accounted for the largest share in Global Stem Cell Therapy Market?

In 2022, North America dominated the stem cell therapy market with the largest revenue share of 44.56%. This can be attributed to several factors, including the presence of innovative companies and key market players in the region, leading to a higher penetration of stem cell therapy products. North America is known for its strong biotechnology industry, extensive research and development activities, and a focus on promoting personalized medicines. These factors contribute to the region's leading position in the market. Additionally, the growth in North America is further supported by government initiatives aimed at promoting stem cell therapies.

Stem Cell Therapy Companies

Stem Cell Therapy Market Competitive Landscape

Top Player’s Company Profiles in Stem Cell Therapy Market

Mesoblast Limited (Australia)
Athersys, Inc. (USA)
Novartis AG (Switzerland)
Osiris Therapeutics, Inc. (USA)
StemCell Technologies Inc. (Canada)
JCR Pharmaceuticals Co., Ltd. (Japan)
Anterogen Co., Ltd. (South Korea)
BrainStorm Cell Therapeutics Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
Pharmicell Co., Ltd. (South Korea)
Cellular Dynamics International, Inc. (USA)
Vericel Corporation (USA)
Holostem Terapie Avanzate S.r.l. (Italy)
Gamida Cell Ltd. (Israel)
BioTime, Inc. (USA)

Stem Cell Therapy Market

FAQs

Global Stem Cell Therapy Market size was valued at USD 12.11 Billion in 2022 poised to grow from USD 13.33 Billion in 2023 to USD 28.79 Billion by 2031, growing at a CAGR of 10.1% in the forecast period (2024-2031).

The global stem cell therapy market is extremely competitive worldwide, with major competitors spearheading research and growth. The global firms like Mesoblast Limited, Athersys, Inc., and Novartis AG have strong R&D pipelines and advanced stem cell drugs. They focus on clinical trials, launches of new products or strategic partnerships as a way of maintaining their competitive edge. Biotech companies are increasingly collaborating with academic institutions in the market to fast track the development of novel therapeutics. 'Mesoblast Limited (Australia) ', 'Athersys, Inc. (USA) ', 'Novartis AG (Switzerland) ', 'Osiris Therapeutics, Inc. (USA) ', 'StemCell Technologies Inc. (Canada) ', 'JCR Pharmaceuticals Co., Ltd. (Japan) ', 'Anterogen Co., Ltd. (South Korea) ', 'BrainStorm Cell Therapeutics Inc. (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pharmicell Co., Ltd. (South Korea) ', 'Cellular Dynamics International, Inc. (USA) ', 'Vericel Corporation (USA) ', 'Holostem Terapie Avanzate S.r.l. (Italy) ', 'Gamida Cell Ltd. (Israel) ', 'BioTime, Inc. (USA)'

Financial assistance from governmental organizations and appropriate regulatory frameworks promotes a conducive atmosphere for stem cell therapy research and development. Increased research efforts and availability of funding for cell-based studies have generally arisen from the need for better and more creative treatment options for autoimmune, neurological, and cardiovascular diseases.

Drug Companies Seek Specialized Talent Amidst Innovation in Therapeutics: As pharmaceutical companies are working on more intricate therapeutic areas and innovative drug delivery systems; they are looking for personnel having experience in the development of new products than at any other time. Increasingly, firms are exporting to companies with a rich history in unique areas like biology and controlled release formulations.

North America leads the global stem cell therapy market due to its robust regulatory backing, significant investments in research and development as well as an elaborate healthcare network. This region also houses key biotech firms and scholarly bodies which stimulates advancement of stem cell technologies. Furthermore, a strong demand for cutting-edge medicines and the increasing frequency of chronic diseases fuel market expansion. The region's leadership is further strengthened by the financing for stem cell research and the supportive policies of the U.S. government. North America's market dominance is further attributed to the existence of significant market players and a firmly structured clinical trial infrastructure.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Stem Cell Therapy Market Competitive Landscape

Stem Cell Therapy Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Stem Cell Therapy Market Competitive Landscape

Stem Cell Therapy Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Stem Cell Therapy Market?

Who are the key vendors in the Stem Cell Therapy Market?

What is the key driver of Stem Cell Therapy Market?

What is the key market trend for Stem Cell Therapy Market?

Which region accounted for the largest share in Stem Cell Therapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300